BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:27 PM
 | 
Feb 26, 2009
 |  BC Extra  |  Top Story

Synta suspends elesclomol trials

Synta (NASDAQ:SNTA) suspended the Phase III SYMMETRY trial of elesclomol to treat stage IV metastatic melanoma after an independent DMC observed a greater number of deaths in the elesclomol arm compared to the control arm. As a result, Synta suspended all other ongoing studies of the oxidative stress inducer, including a Phase...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >